Changeflow GovPing Healthcare EMRELIS Patent Extension Comment Form
Routine Consultation Added Consultation

EMRELIS Patent Extension Comment Form

Email

Summary

FDA has opened a public comment period for EMRELIS patent extension matter via regulations.gov docket FDA-2025-E-3073. The 60-day comment window allows interested parties to submit feedback on the patent term extension application. Commenters may submit as individuals, organizations, or anonymously with attachments up to 10MB.

What changed

This document is a standard comment form template hosted on regulations.gov for submitting public comments on FDA's consideration of a patent term extension for the drug product EMRELIS. The form accommodates comments up to 5,000 characters and allows attachment of up to 20 supporting documents. Submitters must identify as an Individual, Organization, or Anonymous.

Regulated parties interested in the EMRELIS patent extension decision should submit substantive comments within the applicable 60-day window. Commenters should be aware that all submitted information, including attachments, will become part of the public docket and may be publicly disclosed and searchable online. No specific compliance obligations arise from this comment form itself.

Archived snapshot

Apr 3, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

Write a Comment

Commenter's Checklist
Public Comments on Federal Regulations

Comment *

5000

What is your comment about?

Attach Files

You can attach up to 20 files, but each file cannot exceed 10MB. Valid file types include: bmp, docx, gif, jpg, jpeg, pdf, png, pptx, rtf, sgml, tif, tiff, txt, wpd, xlsx, xml. Drop files here or Browse...

Email Address

Opt to receive email confirmation of submission and tracking number?
If you choose to identify as Anonymous, the option to receive an email confirmation will not be displayed. (We will never post the email address entered in the field above on Regulations.gov nor share it with anyone else.)

Tell us about yourself! I am... *

(Select an identity below)

An Individual

Yourself or another person whom
you represent with their consent

An Organization

A company, organization,
or government agency

Anonymous

A person who does not want their name
associated with the comment

Note: If you choose to identify as Anonymous, the option to enter your email address for submission confirmation is not available.

reCAPTCHA *

Do not submit personally identifiable information through this form. Any personally identifiable information (e.g., name, address, phone number) included in the comment form or in an attachment may be publicly disclosed in a docket or on the Internet (via Regulations.gov, a federal agency website, or a third-party, non-government website with access to publicly-disclosed data on Regulations.gov). By submitting a comment, you agree to the terms of participation and privacy notice.

Submit Comment

Please see the Privacy Notice and User Notice regarding comment submission.

Any information (e.g., personal or contact) you provide on this comment form or in an attachment may be publicly disclosed and searchable on the Internet and in a paper docket and will be provided to the Department or Agency issuing the notice. To view any additional information for submitting comments, such as anonymous or sensitive submissions, refer to the Privacy Notice and User Notice, the Federal Register notice on which you are commenting, and the Web site of the Department or Agency.

Named provisions

EMRELIS Patent Extension

Get daily alerts for Regs.gov: Food and Drug Administration

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from FDA.

What's AI-generated?

The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.

Last updated

Classification

Agency
FDA
Instrument
Consultation
Legal weight
Non-binding
Stage
Consultation
Change scope
Minor
Docket
FDA-2025-E-3073

Who this affects

Applies to
Pharmaceutical companies Drug manufacturers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent Term Extension
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Regulatory Affairs
Topics
Intellectual Property Drug Approval

Get alerts for this source

We'll email you when Regs.gov: Food and Drug Administration publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.